In the present study, we examined in vitro biliary clearance of several compounds in sandwich-cultured rat hepatocytes (SCRH) and compared it with that observed in vivo in rats; the effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion was also assessed. The in vitro biliary excretion was determined by differential cumulative uptake of compounds in SCRH preincubated in the presence and absence of Ca 2؉ /Mg 2؉ .
Biliary excretion is one of the important routes for drug elimination (Levine, 1978; Rollins and Klaassen, 1979) . Therefore, elucidating the biliary excretion properties of new chemical entities (NCEs) is a critical issue in the drug discovery and development stage. Several experimental methods have been used to investigate the mechanism of biliary excretion, including liver canalicular membrane vesicles, isolated and cultured hepatocytes, isolated perfused liver, and bile ductcannulated animals (Kukongviriyapan and Stacey, 1990; Tamai et al., 1990; Handler et al., 1994; Chandra et al., 2005; Tsuda-Tsukimoto et al., 2006) . However, because of the lack of acceptable throughput, development of more suitable methods for evaluating the hepatobiliary disposition of NCEs in the drug discovery and development stage is desired.
In view of convenience and an advantage of accessibility, primary cultured rat hepatocytes have been expected to be a potential in vitro tool for evaluating hepatobiliary disposition; however, primary cultured rat hepatocytes are well known for rapidly losing cell polarity and liver-specific functions such as albumin secretion, hepatic uptake, and enzyme activity under conventional monolayer culture conditions (Foliot et al., 1985; Dunn et al., 1989) . In contrast with conventional conditions, hepatocytes cultured in a collagen-sandwich configuration were reported to maintain the liver-specific functions for several days and exhibit a three-dimensional configuration, formation of bile canaliculi, and proper localization of drug efflux transporters on the canalicular membrane (LeCluyse et al., 1994; Talamini et al., 1997) .
Brouwer and colleagues reported an application of sandwich-cultured rat hepatocytes (SCRH) to evaluate biliary excretion (Liu et al., 1999a) . In their technique, biliary excretion in SCRH was assessed by cumulative uptake of a compound in the presence (a standard condition) and absence of Ca 2ϩ /Mg 2ϩ in the incubation medium. The cumulative uptake in the standard condition represented the amount of compound in both cytosol and the bile canalicular lumen, whereas that in the Ca 2ϩ /Mg 2ϩ -free condition represented the amount only in cytosol because the tight junction of bile canaliculi was disrupted under this condition. Therefore, the amount of compound excreted into the bile canalicular lumen was estimated from the differential uptake of compound between standard and Ca 2ϩ /Mg 2ϩ -free conditions.
Recently, sandwich-cultured human hepatocytes have been used to evaluate human biliary excretion (Bi et al., 2006) . Establishing an in vitro-in vivo correlation of biliary excretion is required for the prediction of human hepatobiliary excretion. Previously, the in vitro-in vivo correlation of biliary excretion for Bsep and Mrp2 substrates was evaluated using radiolabeled substrates in SCRH (Liu et al., 1999b) . However, the in vivo intrinsic biliary clearance was calculated on the basis of the plasma total concentration without consideration of the plasma unbound fraction in the correlation study. In addition, although Bcrp is also an important transporter for the biliary excretion of drugs (Hirano et al., 2005; Zamek-Gliszczynski et al., 2005; Ando et al., 2007) , the correlation of Bcrp substrates has not been examined. Furthermore, when the SCRH system is applied to the drug discovery process, it is a great advantage if the assay system is available for unlabeled compounds.
In the present study, we investigated the in vitro biliary clearance of several unlabeled compounds including rosuvastatin as a rat Bcrp substrate (unpublished observation) in SCRH and compared it with their corresponding in vivo intrinsic clearance. Furthermore, the influence of plasma protein binding on the in vitro-in vivo correlation of biliary clearance was assessed. Test compounds such as pravastatin, rosuvastatin, valsartan, cefmetazole, and cefoperazone that were known to be mainly excreted into bile in rats were chosen for the correlation study (Pattinson et al., 1987; García-Agundez et al., 1992; Komai et al., 1992; Nezasa et al., 2002; Yamashiro et al., 2006) . for 1 min in supplemented DMEM. Cell pellets were resuspended with supplemented DMEM, and viability was determined by trypan blue exclusion. Only those cell preparations with greater than 85% viability were used for further studies. To culture the hepatocytes in a collagen-sandwich configuration, the cells were plated onto 24-well collagen-coated culture plates (Asahi Technoglass Corp., Tokyo, Japan) at a density of 2 ϫ 10 5 cells/well in 0.5 ml of supplemented DMEM. Cells were allowed to attach for 2 h at 37 o C in a humidified chamber with 95%/5% of air/CO 2 atmosphere. Then, medium containing unattached cells was aspirated and William's E medium supplemented with 0.1 M dexamethasone, 6.25 g/ml insulin, 6.25 g/ml transferrin, 6.25 ng/ml selenium, and 50 g/ml Matrigel was added to the cultures. The supplemented William's E medium was changed every 24 h for 96 h.
Cumulative Uptake Study in SCRH. The uptake study was carried out according to the method reported previously (Liu et al., 1999a) . SCRH were preincubated in 0.5 ml of standard buffer or Ca 2ϩ /Mg 2ϩ -free buffer at 37 o C for 10 min. The standard buffer was composed of HBSS and 20 mM HEPES, and Ca 2ϩ /Mg 2ϩ -free buffer was composed of Ca 2ϩ /Mg 2ϩ -free HBSS, 20 mM HEPES, and 0.5 mM EGTA. After removal of the buffer by suction, an uptake reaction was initiated by adding 0.5 ml of substrate-containing standard buffer and terminated by rinsing four times with 0.5 ml of ice-cold standard buffer. For radiolabeled compounds, the cells were lysed with 0.5 ml of 1% Triton X-100 in phosphate-buffered saline by shaking for 20 min at room temperature. An aliquot of lysate was analyzed by liquid scintillation spectrometry. A BCA protein assay kit was used to determine the protein concentration in the cell lysate. For unlabeled compounds, cells were lysed with 0.4 ml of acetonitrile-methanol (7:3, v/v) by shaking for 10 min at room temperature, and aliquots of cell lysate were filtered with 0.45-m pore size membrane filters (Nihon Millipore Ltd., Tokyo, Japan). The filtrate was dried in a centrifugal evaporator and reconstituted with an aqueous mobile phase for the LC-MS/MS analysis.
Plasma Concentration and Biliary Excretion in Rats after i.v. Administration. Rats were anesthetized with diethyl ether and the following studies were carried out under light anesthesia. For biliary excretion studies, a polyethylene cannula tube (0.28 mm i.d. and 0.61 mm o.d.; Natsume Seisakusyo Co., Ltd., Tokyo, Japan) was inserted into a common bile duct. The body temperature of rats was maintained by heating with a lamp. Pravastatin, cefmetazole, and cefoperazone were formulated as a solution in saline and rosuvastatin and valsartan in a mixture of saline/dimethylformamide (1:1, v/v) at a concentration of 1 mg/ml. Each compound was administered i.v. via the tail vein at a dose of 1 mg/kg. Blood and bile were collected at the designated time, and the blood was centrifuged to obtain plasma. The plasma or bile samples were mixed with acetonitrile-methanol (7:3, v/v) and centrifuged. The supernatant was analyzed by LC-MS/MS. Plasma Protein Binding. Plasma protein binding of test compounds was determined by an ultracentrifugation technique (Barré et al., 1985) . In brief, 3 l of 1 mM test compound solution in 80% acetonitrile was mixed with 300 l of pooled rat plasma at concentration of 10 M (final acetonitrile concentration, 0.8% v/v). A 200-l aliquot was centrifuged at 436,000g for 4 h at 37°C. Aliquots of the unbound fraction were collected to determine the unbound concentration. The plasma samples without ultracentrifugation were diluted with a 9-fold volume of saline for determination of total plasma concentration. The aliquots of each sample were added to the 9-fold volume of acetonitrile and centrifuged. The supernatants were analyzed by LC-MS/MS. Plasma unbound fraction (f p ) was calculated by f p ϭ C f /C t , where C f and C t represent the drug concentration with and without ultracentrifugation, respectively.
Blood/Plasma Ratio. Fresh blood was obtained in heparinized containers from Sprague-Dawley rats. The blood was spiked with each compound (final concentration at 1 M) and placed in a 37°C shaking water bath for 20 min. Aliquots were withdrawn from the incubation tubes as a blood sample. The remaining blood fraction was centrifuged to separate the plasma and blood cell suspensions, and aliquots of plasma fraction were collected as a plasma sample. The blood or plasma sample was mixed with acetonitrile-methanol (7:3, v/v) and centrifuged. The supernatants were analyzed by LC-MS/MS. The blood/plasma ratio (Rb) was calculated by Rb ϭ C b /C p , where C b and C p represent the blood and plasma concentrations of the compound, respectively. Analytical Procedure. Chromatography was performed on an Acquity UPLC system (Waters, Milford, MA) equipped with an Acquity UPLC BEH C 18 column (50 mm ϫ 2.1 mm, i.d., 1.7-m particle size; Waters) maintained at 40°C. The initial mobile phase was 95% 20 mM ammonium acetate and 5% acetonitrile and the proportion of acetonitrile was linearly increased to 90% over 3 min with the flow rate of 0.3 ml/min. The autosampler was conditioned at 8°C with the injection volume of 3 l.
Mass spectrometry analysis was performed on a Quattro Premier XE tandem quadrupole mass spectrometer (Waters) using an electrospray source in positive or negative ion mode. The ionization source parameters were capillary voltage 1.0 kV; source temperature 120°C; desolvation gas temperature 400°C at a flow rate of 1000 liters/h (nitrogen) and a cone gas flow rate of 50 liters/h. Nitrogen (99.9% purity) and argon (99.9999% purity) were used as cone and collision gases, respectively. The following selected ion monitoring transitions were used for analysis: 423.4 Ͼ 321.1 for pravastatin, 482.2 Ͼ 258.1 for rosuvastatin, 436.2 Ͼ 207.1 for valsartan, 472.1 Ͼ 328.0 for cefmetazole, and 646.2 Ͼ 143.1 for cefoperazone at collision energy of 15, 37, 27, 15, and 41, respectively. The acid form was monitored in the measurement of pravastatin and rosuvastatin because the levels of the lactone form were negligible. Data acquisition was performed with MassLynx version 4.1 software with a QuanLynx program (Waters).
Data Analysis. Apparent intrinsic biliary clearance is defined as intrinsic biliary clearance in the present study. In vitro intrinsic uptake clearance (CL uptake, int ) and intrinsic biliary clearance (CL bile, int ) were estimated according to eq.1 and eq.2, respectively. Rat liver weight and protein content in liver tissue were assumed to be 40 g/kg b.wt. and 200 mg of protein/g liver weight, respectively, in each calculation (Seglen, 1976; Davies and Morris, 1993) .
where ⌬uptake represents the differences of uptake amount between 0 and 2 min and concentration (medium) represents the concentration in the incubation medium at 0 min.
where uptake (ϩCa 2ϩ /Mg 2ϩ ) and uptake (ϪCa 2ϩ /Mg 2ϩ ) represent the cumulative uptake of compound in SCRH preincubated in the presence and absence of Ca 2ϩ /Mg 2ϩ , respectively. The intrinsic biliary clearance was determined at 10 min. Biliary excretion was quantitatively assessed by the biliary excretion index (BEI) at the time point of 10 min based on eq. 3 (Liu et al., 1999c) . BEI was determined using B-CLEAR technology (Qualyst, Inc., Raleigh, NC).
The in vivo kinetic parameters such as AUC inf (area under the plasma concentration-time curve), Vdss (distribution volume), CL tot (total body clearance), C 0 (initial concentration) and t 1/2 (plasma half-life) were calculated by a model-independent method using the MULTI computer program (Yamaoka and Nakagawa, 1983) . The in vivo biliary clearance (CL bile ) was calculated according to eq. 4
where accumulation in bile (180 min) represents the amount of compounds excreted into bile for 180 min and AUC (180 min) represents the area under the plasma concentration-time curve from 0 to 180 min. The in vivo intrinsic biliary clearance was calculated by eq. 5a and 5b using the well-stirred model, where Qh represents rat hepatic blood flow, 67 ml/ min/kg (Nies et al., 1976) , and f p and Rb represent plasma unbound fraction and blood/plasma ratio of test compounds, respectively. In these equations, CL bile, int and CL bile, intЈ represent the intrinsic biliary clearance calculated on the basis of plasma unbound concentration and plasma total concentration, respectively. Figure 1 shows a phase-contrast image of SCRH cultured for 4 days (left) and fluorescence images after a 20-min preincubation with 10 M CDF diacetate in standard buffer (middle) and Ca 2ϩ /Mg 2ϩ -free buffer (right). The formation of bile canalicular lumen was clearly observed in SCRH. The fluorescent Mrp2 substrate, CDF (Kitamura et al., 1990) , was localized in hepatocytes and the bile canalicular lumen when it was incubated in the standard condition. In contrast, CDF localization in the bile canalicular lumen but not in hepatocytes disappeared in Ca 2ϩ /Mg 2ϩ -free condition. These results suggest that the bile canaliculi and intact tight junctions were reestablished and that Mrp2 functioned to accumulate the substrate into the canalicular lumen in SCRH used in this study.
Results

Cell Morphology and Biliary Excretion of CDF in SCRH.
Cumulative Uptake of the Radiolabeled Substrates in SCRH. Several radiolabeled compounds were chosen to assess the function of efflux transporters in SCRH. Figure 3 shows the cumulative uptake of unlabeled compounds that are known to be mainly excreted into bile in vivo, such as pravastatin, rosuvastatin, valsartan, cefmetazole, and cefoperazone. There were differences in cumulative uptake of compounds under standard and Ca 2ϩ /Mg 2ϩ -free conditions except for cefmetazole. Table 2 summarizes intrinsic uptake clearance, intrinsic biliary clearance, and BEI of test compounds in SCRH. The intrinsic uptake clearance, which represents the sinusoidal uptake in hepatocytes, was high for rosuvastatin, intermediate for pravastatin and valsartan, and low for cefmetazole and cefoperazone. BEI, which represents canalicular efflux, was high for rosuvastatin, cefoperazone, pravastatin, and valsartan and low for cefmetazole. The intrinsic biliary clearance, which represents the net biliary excretion, was high for rosuvastatin, intermediate for pravastatin and valsartan, and low for cefmetazole and cefoperazone.
Plasma Concentration and Cumulative Biliary Excretion of Unlabeled Compounds in Rats. Pravastatin, rosuvastatin, valsartan, cefmetazole, and cefoperazone were administered i.v. to common bile duct-cannulated rats at the dose of 1 mg/kg. The plasma concentration-time curve and the cumulative biliary excretion-time curve of test compounds are shown in Fig. 4 . Pharmacokinetic and biliary excretion parameters of test compounds are summarized in Table  3 . All compounds were rapidly eliminated with a plasma half-life within 40 min. Biliary excretions of these compounds were all Ͼ60% of dose.
As shown in Table 3 , the plasma protein binding ratio was extremely high for valsartan, modestly high for rosuvastatin, and low for others. Especially large differences were observed between CL bile, int and CL bile, intЈ of valsartan and rosuvastatin because of their high protein binding. The blood/plasma ratios of pravastatin, rosuvastatin, valsartan, cefmetazole, cefoperazone, and taurocholic acid were 0.65, 0.67, 0.60, 0.66, 0.57, and 0.63, respectively. All test compounds were less distributed to the blood cells.
Comparison of Biliary Excretion between in Vitro and in Vivo. The parameters of in vitro and in vivo biliary excretion of test compounds were compared by several approaches. The following in vivo parameters of taurocholic acid were obtained from the literature: biliary excretion ratio, biliary clearance, and plasma unbound fraction were 100%, 29.8 ml/min/kg, and 0.15, respectively (Inoue et al., 1985) . Based on these parameters, the in vivo intrinsic biliary clearance calculated from eq. 5a and eq. 5b were 675.7 and 160.9 ml/min/ kg, respectively. Figure 5A shows a comparison of the in vivo biliary excretion ratio and the BEI obtained from in vitro study. No clear correlation was observed between these parameters (r 2 ϭ 0.638). Furthermore, the in vitro intrinsic biliary clearances of test compounds were compared with their corresponding in vivo clearances calculated on the basis of plasma total or unbound concentration (Fig. 5, B and C). There was poor in vitro-in vivo correlation (r 2 ϭ 0.217) when the in vivo intrinsic biliary clearances were calculated on the basis of plasma total concentration (CL bile, intЈ ) (Fig. 5B) . In contrast, the in vitro intrinsic biliary clearances were well correlated (r 2 ϭ 0.984) when the in vivo intrinsic biliary clearances were calculated on the basis of plasma unbound concentration (CL bile, int ) (Fig. 5C ). 
Discussion
In the present study, the in vitro biliary excretion was evaluated using SCRH to predict biliary excretion in vivo. First, we investigated whether the SCRH prepared in our study was capable of investigating in vitro biliary excretion or not. The phase-contrast microscopy study revealed that the SCRH exhibited liver-like cell morphology and the formation of bile canaliculi (Fig. 1, left) . When the transporters are expressed and tight junctions are formed adequately, the accumulation of substrates of hepatic efflux transporters can be detected in the bile canalicular lumen; however, the accumulation of substrates in the bile canalicular lumen is not observed under the Ca 2ϩ /Mg 2ϩ -free condition, because the integrity of the tight junctions is Ca 2ϩ /Mg 2ϩ -dependent. As an example, the fluorescent Mrp2 substrate, CDF, was accumulated in bile canalicular lumen under the standard condition (Fig. 1, middle) . However, the accumulation of fluorescence was not observed under the Ca 2ϩ /Mg 2ϩ -free condition (Fig. 1, right) . These 
TABLE 2
Kinetic parameters for in vitro biliary excretion of unlabeled compounds in SCRH
Data are taken from Fig. 3 . All compounds were tested at 1 M except for pravastatin at 10 M. Intrinsic uptake clearance (CL uptake, int ), intrinsic biliary clearance (CL bile, int ), and BEI of test compounds were calculated from eqs. 1, 2, and 3, respectively, as described under Materials and Methods. CL bile, int and BEI were determined at 10 min. Each value represents the mean Ϯ S.E.M. (n ϭ 6). 
IN VITRO-IN VIVO CORRELATION OF BILIARY EXCRETION IN RATS
at ASPET Journals on June 22, 2017 dmd.aspetjournals.org results demonstrated that our SCRH reestablished bile canaliculi and intact tight junctions and that it maintained the functional activity of Mrp2.
Polarized excretion by canalicular membrane transporters is essential for biliary excretion of compounds. Bsep, Mrp2, Bcrp, and Mdr1 are dominant transporters responsible for biliary excretion of endogenous and exogenous substances (Chandra and Brouwer, 2004) . As shown in Fig. 2 and Table 1 , taurocholic acid, estradiol-17␤-Dglucuronide, estrone 3-sulfate, and digoxin, which are substrates for Bsep, Mrp2, Bcrp, and Mdr1, respectively, were excreted into bile canalicular lumen in SCRH. These observations indicated that our SCRH expressed the functional canalicular transporters.
Next, SCRH were applied for the in vitro biliary excretions of unlabeled compounds. The biliary excretion of pravastatin, rosuvastatin, valsartan, and cefoperazone was clearly observed in SCRH, whereas it was negligible in case of cefmetazole (Fig. 3) . The following three parameters were determined in the present study using SCRH: 1) intrinsic uptake clearance for sinusoidal uptake from incubation medium into the cells, 2) BEI for translocation from hepatic intracellular space to bile canalicular lumen, and 3) intrinsic biliary clearance for net biliary excretion from incubation medium to bile canalicular lumen (Table 2) . Rosuvastatin showed high biliary excretion, sinusoidal uptake, and canalicular efflux. Pravastatin and valsartan exhibited intermediate biliary excretion, sinusoidal uptake, and canalicular efflux. The higher uptake of rosuvastatin compared with pravastatin is consistent with the results of a previous report (Nezasa et al., 2003) . Biliary excretions of cefmetazole and cefoperazone were low compared with those of rosuvastatin, pravastatin, and valsartan as were their sinusoidal uptake. Whereas the sinusoidal uptake of cefoperazone into hepatocytes was lower than that of cefmetazole, the canalicular efflux of cefoperazone was fairly higher than that of cefmetazole as reported previously (Nakakariya et al., 2008; Kato et al., 2008) . Consequently, net biliary excretion of cefoperazone was higher than that of cefmetazole. These results suggest that the canalicular membrane transport as well as sinusoidal uptake greatly affects the intrinsic biliary clearance of drugs.
It is important to note that the actual intrinsic biliary clearance should be determined by the transport across the canalicular membrane based on the intracellular unbound concentration of compounds. However, it is practically impossible to determine experimentally the intracellular unbound concentration of compounds in both in vitro and in vivo studies, because many compounds could bind to various intracellular components such as proteins, lipids, DNAs, and others. Accordingly, in vitro biliary intrinsic clearance was calculated on the basis of the unbound concentration in incubation medium instead of the intracellular unbound concentration. Similarly, in vivo biliary intrinsic clearance was calculated on the basis of the plasma unbound concentration. Therefore, the in vitro and in vivo intrinsic biliary clearance in this study should be considered as an "apparent " intrinsic biliary clearance. As shown in Fig. 4 and Table 3 , pravastatin, rosuvastatin, valsartan, cefmetazole, and cefoperazone were excreted mainly into bile with comparable values of their biliary excretion ratios that ranged from 62.7 to 86.3%. In contrast, their biliary intrinsic clearances showed more variability, ranging from 10.5 to 1787.2 ml/min/kg. Even though biliary intrinsic clearance was low, compounds could exhibit high biliary excretion ratios as observed for cefmetazole and cefoperazone. Thus, the biliary excretion ratio was determined not only by biliary intrinsic clearance but also by other factors, such as plasma protein binding, hepatic blood flow, and metabolic and renal clearances.
In the present study, the in vitro and in vivo biliary excretions were compared by several approaches. When the in vivo biliary excretion ratio was compared with BEI, there was no good relationship between them (Fig. 5A) . As described previously, BEI reflected the translocation of compound from intracellular space to canalicular lumen across canalicular membrane. At present, it is difficult to predict the in vivo biliary excretion ratio directly from the parameters of SCRH. Subsequently, we also compared the in vitro intrinsic biliary clearance with that in vivo. The in vitro intrinsic biliary clearances of test compounds were well correlated with their corresponding in vivo clearances when the in vivo clearances were calculated on the basis of plasma unbound concentrations (r 2 ϭ 0.984), whereas less correlation were observed when they were calculated on the basis of plasma total concentrations (r 2 ϭ 0.217). It has been well recognized that only protein-unbound substrates but not protein-bound ones are transported and metabolized (Obach, 1999; Takahashi et al., 1999; Takeda et al., 2002) . The in vitro biliary excretion was determined under protein-free conditions in the present SCRH experiments. Therefore, in vitro results should be compared with in vivo biliary excretion profiles based on the plasma unbound fraction. These results indicated that it was essential for a good in vitro-in vivo correlation to consider the plasma unbound fraction and that the in vitro intrinsic biliary clearance was the best parameter for the prediction of the in vivo biliary excretion profile.
In our preliminary study using rat Bcrp-expressing membrane vesicles, it was shown that rosuvastatin could be a substrate of rat Bcrp (unpublished observation). This is the first report to successfully demonstrate the good in vitro-in vivo correlation of intrinsic biliary clearance using a Bcrp substrate. Our SCRH system turned out to be applicable to a diverse range of compounds in drug discovery and development stages.
To apply the SCRH assay system to drug discovery, we made some improvement in the present study. Instead of 60-mm plastic culture dishes with a thick gelled collagen substratum and an overlaid thick gelled collagen, we used 24-well plates with a rigid collagen substratum (collagen-coated plate) and an overlaid thin collagen layer according to a previous report (Sidhu et al., 1993) . The application of 24-well plates reduced the amount of hepatocytes and test compounds. In addition, it was easier to keep the configuration of the collagen layer in a thin form than in a thick one. In addition, LC-MS/MS enabled us to quantify the uptake amount of unlabeled compounds at low nanomolar concentrations and to perform the assay with acceptable throughput. The present modified experimental methods of SCRH help us apply the in vitro system to an early drug discovery stage, which requires high throughput and generality.
In a drug discovery and development stage, it is also important to elucidate whether the elimination pathway of NCEs is single or multiple. It is undesirable for NCEs to have a single elimination pathway from the viewpoint of the alteration of elimination clearance caused by drug-drug interactions and/or genetic polymorphisms on drug transporters and/or metabolizing enzymes. By comparing the present prediction of in vivo biliary clearance with in vivo metabolic clearance predicted from conventional experiments, the contribution of biliary excretion to total clearance can be estimated. Therefore, the sandwich culture system is a useful tool not only for the prediction of hepatobiliary disposition of NCEs but also for estimating the possible alteration of hepatic clearances.
In summary, the present study demonstrates that SCRH is a useful in vitro model to predict in vivo biliary excretion of a diverse range of compounds including Bcrp substrates. Plasma protein binding has a large impact on in vivo biliary intrinsic clearance, especially for highly bound compounds. In additional, to achieve an accurate prediction, it is necessary to calculate the in vivo intrinsic biliary clearance on the basis of plasma unbound concentration.
